ResearcherWashington University in St. LouisActive in the last 2 years
John M. Baer
Matched on ORCID iD 0000-0002-8758-0030; NIH RePORTER profile ID 15167841. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 3, last author 0)
- Trials
- 0
- Grants
- 1
- Labs led
- 0
- Collaborators
- 34
2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper, 1 grant · 2023: 4 papers · 2024: 1 paper · 2025: 1 paper
Papers 9
- Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1821↗
- Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-23-0428↗
- Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology. Co-author DOI 10.1007/s00262-023-03463-x↗
- Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. Co-author DOI 10.1038/s41590-023-01579-x↗
- Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. First author DOI 10.1084/jem.20212062↗
- Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. First author DOI 10.1158/2326-6066.cir-21-0946↗
- Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Co-author DOI 10.1038/s41588-022-01157-1↗
- Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.02.008↗
- Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. First author DOI 10.1038/s41467-018-03600-6↗
Grants 1
Closest collaborators
The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- David G DeNardo · 8 shared papers, 2018–2025 · strength 1.09
- Paper Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-24-1821↗
- Paper Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0428↗
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Ryan C Fields · 6 shared papers, 2018–2024 · strength 0.76
- Paper Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0428↗
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. DOI 10.1038/s41590-023-01579-x↗
- William G. Hawkins · 5 shared papers, 2018–2023 · strength 0.59
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Varintra E. Lander · 4 shared papers, 2020–2024 · strength 0.55
- Paper Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0428↗
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Kian‐Huat Lim · 3 shared papers, 2023–2025 · strength 0.47
- Paper Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-24-1821↗
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Liang‐I Kang · 3 shared papers, 2023–2024 · strength 0.47
- Paper Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0428↗
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. DOI 10.1038/s41590-023-01579-x↗
- Li Ding · 3 shared papers, 2023–2024 · strength 0.45
- Paper Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0428↗
- Paper Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. DOI 10.1038/s41590-023-01579-x↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- C. Alston James · 3 shared papers, 2023 · strength 0.43
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Graham D. Hogg · 3 shared papers, 2020–2023 · strength 0.38
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Paper Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. DOI 10.1016/j.ccell.2020.02.008↗
- Chong Zuo · 3 shared papers, 2020–2023 · strength 0.37
- Paper Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. DOI 10.1038/s41590-023-01579-x↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Paper Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. DOI 10.1016/j.ccell.2020.02.008↗
- Jad I. Belle · 2 shared papers, 2023–2024 · strength 0.31
- Paper Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0428↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Usman Younis Panni · 2 shared papers, 2023 · strength 0.29
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- Patrick M. Grierson · 1 shared paper, 2025 · strength 0.19
- Katrina Sophia Pedersen · 1 shared paper, 2025 · strength 0.19
- Andrea Wang‐Gillam · 1 shared paper, 2025 · strength 0.19
- Blake E. Sells · 1 shared paper, 2024 · strength 0.17
- Paolo Provenzano · 1 shared paper, 2024 · strength 0.17
- Guhan Qian · 1 shared paper, 2024 · strength 0.17
- Hyun Jee Kim · 1 shared paper, 2024 · strength 0.17
- Feng Gao · 1 shared paper, 2023 · strength 0.14
- Yu Zhu · 1 shared paper, 2023 · strength 0.14
- Daoxiang Zhang · 1 shared paper, 2023 · strength 0.14
- William E. Gillanders · 1 shared paper, 2023 · strength 0.14
- Paarth B. Dodhiawala · 1 shared paper, 2023 · strength 0.14
- Daniel Cui Zhou · 1 shared paper, 2023 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.